Home / Guides / Psychedelic therapy in Switzerland
Guide · Europe · Switzerland

Psychedelic therapy in Switzerland (2026): limited medical use, who qualifies and what it costs

Last updated · Trial statuses checked 19 November 2026 · Published by Psyche Vibes Ltd, London

For Swiss residents only. The Federal Office of Public Health (FOPH, in German BAG) issues these exceptional licences only to doctors authorised to practise in Switzerland, for patients resident in Switzerland (FOPH). This is not a route for visitors, and this page is not a travel or treatment-tourism guide.

The short answer. LSD, MDMA and psilocybin are banned narcotics in Switzerland, and none is an authorised medicine. But the FOPH can grant a treating doctor an exceptional licence for limited medical use for one named patient, when other treatments have been exhausted (Narcotics Act, art. 8(5); FOPH). In 2024 about 100 doctors held such licences for 723 patients (Liechti et al. 2025).

Basic health insurance does not pay for the substance or the long supervised sessions, so most patients pay themselves (FOPH expert report; SÄPT).

At a glance

QuestionWhat the sources say
Who appliesOnly the treating doctor, on a hand-signed paper application with the patient's written consent. Patients cannot apply themselves (FOPH).
Who can be treatedPatients resident in Switzerland, treated by a doctor authorised to practise there (FOPH).
SubstancesLSD, MDMA and psilocybin. MDMA and LSD have been used under the current programme since 2014, and psilocybin since 2021 (expert report).
Licence lengthUsually 12 months, during which the number of sessions is not fixed. It can be extended with a progress report. The FOPH usually issues a licence within two weeks (expert report).
Who paysBasic health insurance does not cover the substance or the long supervised sessions; only ordinary psychotherapy is covered (expert report; SÄPT).
Scale (2024)About 100 licensed doctors, 723 patients and about 1,660 treatment sessions (Liechti et al. 2025).

The legal basis

Article 8(5) of the Narcotics Act lets the FOPH grant exceptional licences for banned narcotics (NarcA). The FOPH lists three purposes: limited medical use, scientific research and drug development (FOPH). For limited medical use, the FOPH says all of these conditions must be met (FOPH):

The application must name the pharmacy source of the substance and say how the treatment will be paid for. A doctor's first application should show relevant experience, such as further training, membership of professional bodies or exchange with experienced physicians. The FOPH monitors licence holders, can inspect on site, and must be told of any serious adverse event within seven working days. Doctors send progress reports to extend a licence and a final report when treatment ends (FOPH).

The substances are not authorised medicines. They are made by a pharmacy for the individual patient, as a magistral preparation. The expert report says a separate compassionate use route through the medicines agency Swissmedic did not exist for psychedelics (data to the end of 2024) (expert report).

Why it is for residents only

The FOPH says it issues limited medical use licences only to doctors authorised to practise in Switzerland, for patients resident in Switzerland (FOPH). The professional society SÄPT says licences apply only to people living in Switzerland, and that patients should live within reach of their therapist (SÄPT). The FOPH also says that trade in banned narcotics for limited medical use abroad cannot be authorised (FOPH).

If you live outside Switzerland, the lawful options are those in your own country, usually clinical trials. See our guides for the UK, Germany and Czechia, and the EU approval status.

Who is treated, and for what

SÄPT says treatment can be licensed only after conventional options have been tried without success, and that the doctors who do it have very limited capacity for new patients (SÄPT). In 2024, depressive disorders were the main diagnosis in 60% of licences and post-traumatic stress disorder (PTSD) in 16%, followed by anxiety disorders (8%) and substance use disorders, mainly alcohol (5%). Depression was mostly treated with psilocybin, and PTSD mostly with MDMA (expert report).

The expert report lists the main reasons demand is only partly met: too few trained doctors, busy schedules, the licensing requirement and the lack of health insurance cover (expert report).

What it costs, and what insurance pays

The programme in numbers

The current programme began in 2014 with two doctors (Liechti et al. 2025). The table shows exceptional licences issued by the FOPH, including continuations, as given in the expert report. A licence usually lasts 12 months and covers several sessions (expert report, p. 12).

FOPH exceptional licences for limited medical use, by substance and year
YearLSDMDMAPsilocybinTotal
2021515343147
20226889104261
2023118146244508
2024128236322686

A peer-reviewed description of the same programme counts 723 patients in 2024 (348 psilocybin, 245 MDMA, 130 LSD), with patients typically treated two to four times within 12 months (Liechti et al. 2025). We have not found official figures for 2025 or 2026.

How people find a doctor

There is no central booking system. SÄPT publishes a list of doctors who have carried out FOPH-licensed treatment, by region; they are not necessarily SÄPT members, and SÄPT warns that they have very limited capacity (SÄPT). Public and university services in our directory include UPK Basel, the Psychiatric University Hospital Zurich and Geneva University Hospitals (HUG). Each sets its own criteria. We list them as facts, not recommendations. Speak to your own psychiatrist or GP first.

Tracker status

From the Switzerland tracker row (data as of 19 November 2026): Not EU: case-by-case exceptional licence per patient, applied for by the treating doctor. Licences only for doctors authorised to practise in Switzerland, for patients resident in Switzerland. 2024: about 100 licensed doctors, 723 patients (psilocybin 348, MDMA 245, LSD 130), about 1,660 sessions; not covered by basic health insurance

Psychedelic trials recruiting in Switzerland

Generated from the Psyche Insights directory. Trials are a separate route from limited medical use, with their own entry rules. Check the registry record and contact the study team.

Recruiting trial

Antidepressant Response of DMT Masked With Propofol

Condition
Major Depressive Disorder, Psychedelic Experiences
Sponsor
University Hospital, Basel, Switzerland
Swiss sites
Basel
Status
Recruiting (ClinicalTrials.gov)
Registry record
ClinicalTrials.gov NCT06927076
Last checked
19 November 2026
Recruiting trial

LSD Treatment for Persons With Alcohol Use Disorder

Condition
Alcohol Use Disorder (AUD)
Sponsor
Felix Mueller
Phase
Phase 2
Swiss sites
Basel, Bern
Status
Recruiting (ClinicalTrials.gov)
Registry record
ClinicalTrials.gov NCT05474989
Last checked
19 November 2026
Recruiting trial

Lysergic Acid Diethylamide (LSD) in Palliative Care

Condition
Palliative Care, Pain, Anxiety
Sponsor
University Hospital, Basel, Switzerland
Phase
Phase 2
Swiss sites
Basel, Collonge-Bellerive, Uster, Zurich
Status
Recruiting (ClinicalTrials.gov)
Registry record
ClinicalTrials.gov NCT05883540
Last checked
19 November 2026

When could a psychedelic medicine be authorised?

Writing in February 2025, the expert report did not expect a commercial authorisation of any of these substances in Switzerland before 2028 to 2030 (expert report). For the US, UK and EU filings, see our approval tracker and EMA tracker.

Questions and answers

Is psychedelic therapy legal in Switzerland?

Only in narrow, licensed settings. LSD, MDMA and psilocybin are banned narcotics and none is an authorised medicine. The Federal Office of Public Health (FOPH) can grant a treating doctor an exceptional licence to use one of them for a specific patient (limited medical use, Narcotics Act article 8(5)). Otherwise they can be used only in authorised research.

Can I travel to Switzerland for psilocybin or MDMA therapy?

In general, no. The FOPH says it issues these licences only to doctors authorised to practise in Switzerland, for patients resident in Switzerland. The Swiss professional society SÄPT adds that patients should live in their therapist's region. The FOPH also says supplying banned narcotics for limited medical use abroad cannot be authorised.

Who can get a limited medical use licence?

The treating doctor applies, never the patient, with the patient's written consent. All of these must apply: the disease is usually incurable, the substance can relieve the suffering, available treatments have been exhausted or there is no alternative, and the treatment gives the patient a more independent life, for example by avoiding inpatient care.

How much does psychedelic-assisted therapy cost in Switzerland?

Basic health insurance does not pay for the substance or for the long supervised sessions, so patients usually pay themselves; only ordinary psychotherapy is covered. The FOPH-commissioned expert report gives CHF 3,000 to 4,000 as the cost of a single treatment with preparation and follow-up, in a model where supplementary insurance might cover it.

How many people are treated?

In 2024 about 100 doctors held licences to treat 723 patients: 348 with psilocybin, 245 with MDMA and 130 with LSD. There were about 1,660 treatment sessions, and patients were typically treated two to four times within 12 months.

Are psilocybin retreats legal in Switzerland?

We found no lawful basis for them. The FOPH lists only three purposes for exceptional licences for banned narcotics: limited medical use by a licensed doctor for a resident patient, scientific research and drug development. This guide covers only the medical route.

Get UK and Europe access news each week

New trials, regulator decisions and law changes, with every claim linked to its source. Free, one email a week.

Subscribe free →

Sources

Hand-written facts and links checked 19 November 2026. Trial records checked on the dates shown.

  1. Swiss Federal Office of Public Health (FOPH): limited medical use of banned narcotics. https://www.bag.admin.ch/en/limited-medical-use-of-banned-narcotics
  2. FOPH: exceptional licences for banned narcotics. https://www.bag.admin.ch/en/exceptional-licences-for-banned-narcotics
  3. Federal Act on Narcotics and Psychotropic Substances (Narcotics Act, NarcA), SR 812.121, art. 8 (Fedlex). https://www.fedlex.admin.ch/eli/cc/1952/241_241_245/en
  4. Liechti M. Expert report for the FOPH: limited medical treatment with psychedelics and MDMA in Switzerland, 2nd edition, February 2025, data to 31 December 2024 (German, PDF). https://www.bag.admin.ch/dam/de/sd-web/7g3b6SYAsiyU/Expertenbericht%20BAG%20Aerzte%20Hallus%20MDMA%20Liechti_2025.pdf
  5. Liechti ME et al. Implementing psychedelic-assisted therapy: history and characteristics of the Swiss limited medical use program. Neuroscience Applied, 2025. https://doi.org/10.1016/j.nsa.2025.105525
  6. SÄPT: limited medical use, information for people interested in treatment (German). https://saept.ch/fuer-interessentinnen/